文献速递肿瘤 PET/CT

使用89Zr-曲妥珠单抗PET无创评估食管胃癌中人表皮生长因子受体2(HER2)的表达:一项先导研究

Noninvasive Assessment of Human Epidermal Growth Factor Receptor 2 (HER2) in Esophagogastric Cancer Using 89Zr-Trastuzumab PET: A Pilot Study.
PubMed 文献 · J Nucl Med · 2022-11-23

该先导研究对33例HER2阳性转移性食管胃癌患者行89Zr-曲妥珠单抗PET(HER2 PET)和CT检查,其中26例同时行18F-FDG PET。18F-FDG PET识别病灶数中位7个多于HER2 PET的4个;33例中23例(70%)为HER2影像阳性。作者认为HER2 PET可能识别HER2表达异质性并评估全身病灶。

要点

  • 18F-FDG PET识别病灶数中位7个(范围1-14),多于HER2 PET的4个(范围0-11)。
  • 33例中23例(70%)为HER2影像阳性(≥50%肿瘤负荷阳性),仅10例100%肿瘤负荷阳性。
  • 接受一线HER2靶向治疗者中,有和无强或极强病灶(SUV≥10)者的中位无进展生存期无显著差异(P=0.35)。

核心结论

  • HER2 PET可能识别HER2表达的异质性并评估全身病灶。
  • HER2 PET的潜在应用包括无创评估HER2状态,以及评估标准影像或单部位活检未能捕捉的患者内疾病异质性。

研究设计与样本

  • 先导研究,纳入33例HER2阳性转移性食管胃癌患者,行HER2 PET和CT检查,其中26例同时行18F-FDG PET。
  • 肿瘤类型分布为食管腺癌12%、胃食管交界处腺癌64%、胃腺癌24%。

主要发现

  • 18F-FDG PET识别病灶数中位7个(范围1-14),多于HER2 PET的4个(范围0-11)。
  • HER2 PET识别而18F-FDG PET未识别的8个病灶中,3个(38%)位于骨,1个位于脑。
  • 18F-FDG PET识别而HER2 PET未识别的68个病灶中,4个(6%)位于骨,其余位于淋巴结(35个,51%)和肝脏(16个,24%)。
  • 33例中23例(70%)为HER2影像阳性(≥50%肿瘤负荷阳性),仅10例100%肿瘤负荷阳性,2例0%阳性。
  • 仅分析接受一线HER2靶向治疗的13例患者时,HER2影像阳性与阴性患者的中位无进展生存期无显著差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Variations in human epidermal growth factor receptor 2 (HER2) expression between the primary tumor and metastases may contribute to drug resistance in HER2-positive (HER2+) metastatic esophagogastric cancer (mEGC). 89Zr-trastuzumab PET (HER2 PET) holds promise for noninvasive assessment of variations in HER2 expression and target engagement. The aim of this study was to describe HER2 PET findings in patients with mEGC. Methods: Patients with HER2+ mEGC were imaged with HER2 PET, 18F-FDG PET, and CT. Lesions were annotated using measurements (on CT) and maximum SUVs (on HER2 PET). Correlation of visualized disease burden among imaging modalities with clinical and pathologic characteristics was performed. Results: Thirty-three patients with HER2+ mEGC were imaged with HER2 PET and CT (12% esophageal, 64% gastroesophageal junction, and 24% gastric adenocarcinoma), 26 of whom were also imaged with 18F-FDG PET. More lesions were identified on 18F-FDG PET (median, 7 [range, 1-14]) than HER2 PET (median, 4 [range, 0-11]). Of the 8 lesions identified on HER2 but not on 18F-FDG PET, 3 (38%) were in bone and 1 was in the brain. Of the 68 lesions identified on 18F-FDG but not on HER2 PET, 4 (6%) were in bone and the remainder were in the lymph nodes (35, 51%) and liver (16, 24%). Of the 33 total patients, 23 (70%) were HER2 imaging-positive (≥50% of tumor load positive). Only 10 patients had 100% of the tumor load positive; 2 had 0% positive. When only patients receiving HER2-directed therapy as first-line treatment were considered (n = 13), median progression-free survival (PFS) therapy was not significantly different between HER2 imaging-positive and -negative patients. Median PFS for patients with at least 1 intense or very intense lesion (SUV ≥ 10) was 16 (95% CI: 11-not reached) mo (n = 7), compared with 12 (95% CI: 6.3-not reached) mo for patients without an intense or very intense lesion (n = 6) (P = 0.35). Conclusion: HER2 PET may identify heterogeneity of HER2 expression and allow assessment of lesions throughout the entire body. A potential application of HER2 PET is noninvasive evaluation of HER2 status including assessment of intrapatient disease heterogeneity not captured by standard imaging or single-site biopsies.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Lumish MA, Maron SB, Paroder V, et al. Noninvasive Assessment of Human Epidermal Growth Factor Receptor 2 (HER2) in Esophagogastric Cancer Using 89Zr-Trastuzumab PET: A Pilot Study. J Nucl Med. 2022. PMID: 36418168. doi:10.2967/jnumed.122.264470

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。